A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma.

In a prospective controlled clinical trial, 108 patients with pancreatic adenocarcinoma were randomly allocated to receive tamoxifen 20 mg b.d., cyproteron acetate 100 mg t.d.s. or no active treatment. The median survival of those receiving tamoxifen was longer than either of the other two groups (5...

Descripción completa

Detalles Bibliográficos
Autores principales: Keating, J. J., Johnson, P. J., Cochrane, A. M., Gazzard, B. G., Krasner, N., Smith, P. M., Trewby, P. N., Wheeler, P., Wilkinson, S. P., Williams, R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1989
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247314/
https://www.ncbi.nlm.nih.gov/pubmed/2529892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2247314/
https://www.ncbi.nlm.nih.gov/pubmed/2529892

Ejemplares similares